Pharmaceuticals
Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines
SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-05-13 08:30
3761
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022
GAITHERSBURG, Md. and SUZHOU, China, May 11, 2022 /PRNewswire/ -- Sirnaomics
Ltd.
2022-05-11 13:05
3746
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functi...
2022-05-11 08:40
4293
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide
STOCKHOLM, Sweden, May 11, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company,announced on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally reported, cleaned and...
2022-05-11 06:42
2517
Bora Pharmaceuticals acquires Eden Biologics CDMO Assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market TAIPEI, May 10, 2022 /PRNewswire/ -- Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the esta...
2022-05-10 17:53
5093
OMRON Healthcare Unveils Long-term Corporate Vision, "Going for ZERO, Preventive Care for Health of Society"
- Aiming to Realize 3 Zeros: "Zero Cerebrovascular and Cardiovascular Events," "Zero Aggravation of Respiratory Diseases" and "Zero Restrictions on Daily Activities Due to Chronic Pain" - KYOTO, Japan, May 10, 2022 /PRNewswire/ -- In March 2022, OMRON Group announced a new long-term vision, "Sha...
2022-05-10 13:00
4004
Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse
* The Consortium jointly, through Aztiq II HoldCo, has completed the acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo * Róbert Wessman, Chairman and CEO of Alvogen and Founder of Aztiq Pharma ...
2022-05-10 11:00
3151
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant * Review of the monoclonal antibody combination therapy is underway by the U.S. Food and Drug Administration (FDA) for Emergency Use Auth...
2022-05-09 19:46
3784
Series A financing round lays foundation for international growth of digital cancer therapeutics Mika
New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika – an app-based DTx platform empowering people affected by cancer. BERLIN, LAUSANNE,Switzerland, BARCELONA,Spain and MUNICH, May 9, 2022 /PR...
2022-05-09 19:35
2739
Takeda Malaysia receives coveted HR accolades by creating an exceptional people experience
Key points: * Takeda Malaysia receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Malaysia in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. * ...
2022-05-09 09:05
3009
Takeda Singapore receives coveted HR accolades by creating an exceptional people experience
Key points: * Takeda Singapore receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Singapore in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. ...
2022-05-09 09:00
2952
ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome
* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...
2022-05-09 07:00
5288
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-07 09:00
6741
Antengene to Participate in Three Upcoming Investor Conferences in May/June
CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...
2022-05-06 08:30
3719
Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...
2022-05-06 05:00
3849
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...
2022-05-05 23:00
3760
HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study
Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...
2022-05-05 22:12
6126
TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®
VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...
2022-05-05 20:40
1937
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV
TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received the clinical trial approval (the "Clinical Trial Approval") for its recombin...
2022-05-05 11:55
4304
First Patient Dosed in Phase II Renal Cancer Theranostics Study
MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...
2022-05-05 05:00
3377
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 313 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
Most Read
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
10335
